Barclays Maintains Equal-Weight on Teladoc Health, Raises Price Target to $9
Barclays analyst Glen Santangelo maintains Teladoc Health (NYSE:TDOC) with a Equal-Weight and raises the price target from $7 to $9.
Share
Why It Matters
A money expert says Teladoc is worth more money than before. But they still think the stock is fairly priced right now.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.